1988810334497112064

Membrane protein Series

Drug Target Encyclopedia Series (38) —DLL3

Drug Target Encyclopedia Series (38) —DLL3

DLL3, also known as **Delta-like Ligand 3**, is an inhibitory Notch pathway ligand with limited expression in most normal adult tissues but high expression in several neuroendocrine tumors. Due to its tumor-selective expression profile, DLL3 has become an important target in oncology drug development, especially in small cell lung cancer. DLL3 is highly relevant in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma, neuroendocrine prostate cancer, and other neuroendocrine tumor research. Its cell-surface expression makes it particularly attractive for antibody-based and targeted therapeutic strategies.

Membrane protein Series

May 29,2026

Drug Target Encyclopedia Series (37) —STEAP1

Drug Target Encyclopedia Series (37) —STEAP1

STEAP1, also known as Six-Transmembrane Epithelial Antigen of the Prostate 1, is a tumor-associated cell surface antigen highly expressed in prostate cancer and several other solid tumors. With its multi-pass membrane structure and relatively restricted expression in normal tissues, STEAP1 has become an attractive target for next-generation oncology drug development. STEAP1 is gaining strong attention in advanced prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), where there remains a significant need for differentiated targets beyond existing prostate cancer therapies. Its membrane localization makes it highly relevant for antibody-based, cell therapy, and targeted delivery approaches.

Membrane protein Series

Apr 24,2026

Drug Target Encyclopedia Series (36) —CD152

Drug Target Encyclopedia Series (36) —CD152

CD152 (CTLA-4) is a well-established immune checkpoint receptor primarily expressed on activated T cells and regulatory T cells (Tregs). By competing with CD28 for binding to CD80/CD86, CTLA-4 acts as a negative regulator of T-cell activation and plays a central role in maintaining immune homeostasis. CTLA-4 has become one of the most important targets in cancer immunotherapy, especially in the development of checkpoint inhibitors and next-generation immune modulators. It is also highly relevant in autoimmune disease research, Treg biology, and combination immuno-oncology strategies.

Membrane protein Series

Apr 16,2026

Drug Target Encyclopedia Series (35) —FGFR3

Drug Target Encyclopedia Series (35) —FGFR3

FGFR3 is a receptor tyrosine kinase that regulates cell growth, differentiation, and tissue development. When aberrantly activated by mutation, fusion, or overexpression, FGFR3 becomes a high-value therapeutic target across oncology and rare genetic disease. In drug discovery, FGFR3 is best known for its role in urothelial carcinoma and skeletal dysplasia, making it one of the few membrane protein targets with both oncology and non-oncology relevance. FGFR3 alterations are clinically actionable in urothelial carcinoma, and erdafitinib is FDA-approved for adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations.

Membrane protein Series

Mar 31,2026

Drug Target Encyclopedia Series (34) —TIGIT

Drug Target Encyclopedia Series (34) —TIGIT

TIGIT is an inhibitory immune checkpoint receptor expressed on activated T cells, NK cells, and regulatory T cells (Tregs). By interacting mainly with CD155 (PVR), TIGIT suppresses anti-tumor immunity and contributes to immune evasion in the tumor microenvironment (TME). Because of its central role in T-cell exhaustion, NK-cell dysfunction, and Treg-mediated immunosuppression, TIGIT has become one of the most closely watched next-generation immuno-oncology targets.

Membrane protein Series

Mar 24,2026

Drug Target Encyclopedia Series (33) —NCR2

Drug Target Encyclopedia Series (33) —NCR2

NCR2, also known as NKp44, is a natural cytotoxicity receptor mainly expressed on activated NK cells. As a key membrane protein in innate immunity, NCR2 supports tumor recognition, NK-cell activation, and cytokine release. In immuno-oncology, NCR2 is gaining attention as a promising target for NK-cell engager design, CAR-NK engineering, and next-generation cell therapy development.

Membrane protein Series

Mar 17,2026

< 1234...8 >